Wana Products on Tuesday announced the launch of WanaCaps XR, a family of extended release cannabis capsules that provide medicinal benefits for up to 12 hours.
Wana Products partnered with Cannabics Pharmaceuticals Inc., a United States-based Drug Development Company with research and development in Israel, that developed the proprietary technology behind the extended release formulation.
WanaCaps XR will be offered in three different formulations: capsules with a 10:1 CBD to THC ratio (WanaCaps XR High CBD Capsules), a 10:1 THC to CBD ratio (WanaCaps XR High THC Capsules), and a balanced formulation with 1:1 THC:CBD ratio (WanaCaps XR THC/CBD Balanced Capsules).
“WanaCaps XR represents the next generation in the evolution of marijuana for the medical community,” said Nancy Whiteman, co-owner of Wana Products. “The extended release formulation enables patients to dose once or twice daily so they can get on with their lives without the constant need to be thinking about re-dosing. Additionally, WanaCaps XR are formulated to be highly bio-available so patients feel the therapeutic impact quickly.”
“The new capsules also address one of the major concerns of cannabis patients, which is that the initial high peak of cannabinoid activity soon after administration which can cause uncomfortable side effects such as disorientation and dizziness,” Whiteman said. “Instead, with WanaCaps XR, patients experience a long-lasting, stable effect for up to 10 hours without the ups and downs. Overall, it’s just a much better experience for patients.”
As the possibilities for cannabis-based treatments continue to make headlines in the medical world, One World Cannabis, a medical-cannabis research company, has announced that the initial results of its landmark study on treating multiple myeloma with cannabis-based solutions were extremely promising. After a series of tests using cannabis-based treatments, researchers were able to eradicate 60 percent of multiple myeloma cells.
The disease is one of the most deadly hematologic cancers and individuals diagnosed with the disease often have about a 50 percent survival rate.
OWC Pharmaceutical Research Corp. on Wednesday announced that its wholly owned subsidiary, One World Cannabis Ltd., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, has received the first basic science study (lab) results on the effect of several combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.
Based on the results, One World Cannabis will submit the clinical trial protocol to the IRB (Helsinki committee). The company expects to receive institutional review board approval for the study within 6-9 weeks.
The OWC multiple myeloma study was done by three repetitive tests on the effect of cannabis extract with various combination ratios of THC/CBD and pure THC and CBD (50 percent concentration). The results present more than 60 percent malignant cell death. More results of pure THC and CBD are under further analysis.
DigiPath Labs of Las Vegas, the cannabis testing subsidiary of DigiPath, Inc., on Thursday announced that it has successfully completed its first commercial test of cannabis material.
In the short time it's been open, the company said it has already proven that it has the equipment and knowledge needed to reliably test medical cannabis for safety and potency.
"We are open for business," said Todd Denkin, president of DigiPath Labs. "It's been a very long and arduous process, but we jumped through all the hoops and cleared all the obstacles, and now we're testing cannabis products and generating revenue, an important milestone to our shareholders."
As one of only two labs currently operating in Southern Nevada, DigiPath Labs is positioned at the forefront of what is anticipated to become a rapidly growing industry in the Silver State. According to ArcView, the legal cannabis market exploded from $1.5 billion in 2013 to $2.7 billion in 2014—a 74 percent increase in just one year.
Greenwave Advisors estimates that the market could reach $35 billion by 2020 if marijuana is fully legalized across the country, or $21 billion under the more likely scenario of 12 states legalizing recreational use and 37 states legalizing medical use.
A U.S.-based company on Thursday announced that it has filed an exclusive patent application with the United States Patent & Trademark Office on a system designed give personalized anti-tumor treatments to cancer patients using cannabinoid therapy.
Cannabics Pharmaceuticals Inc. (CNBX) announced announced the patent application on "a System and Method for High Throughput Screening of Cancer Cells."
In this proprietary system, biopsies are treated, in-vitro, with numerous plant extract combinations and the anti-tumor effects are screened and calculated. The results could enable cancer patients to receive cannabinoid based therapy with a potential of reducing their tumors, according to the company.
Cannabics Pharmaceuticals announced it plans to complete the development of this novel and sophisticated technology and license it by the end of 2016.
"Cannabinoids are known for their anti-tumor properties, and this natural personalized therapy could be highly effective and without side effects, thus benefiting millions of patients worldwide," said Dr. Eyal Ballan, chief scientist of the company.
InMed Pharmaceuticals Inc. on Tuesday announced it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies (plant-based cannabinoids) to treat ocular allergic symptoms.
The collaboration will leverage InMed's proprietary Intelligent Cannabinoid Drug Design Platform (IDP) and will be led by one of the world's leading cannabinoid researchers, Dr. Tamas Biro, MD, PhD, DSc. Dr. Biro has extensive research experience in studying the endocannabinoid system (ECS) and the closely related transient receptor potential (TRP) channels in various human diseases.
Under the discovery and development collaboration InMed's IDP Platform will be used to identify cannabinoid- and non-cannabinoid-based phytochemicals for ocular therapies focused on reducing various pro-inflammatory cytokines in in vitro and in vivo models.
"We have accumulated significant experience and expertise in developing cannabinoids to treat ocular disease, which forms the basis of this strategic collaboration," said Dr. Sazzad Hossain, chief scientific officer of InMed. "As we prepare to initiate Phase 1 clinical trials of our lead phytocannabinoid-based drug candidate CTI-085 for glaucoma, we look forward to expanding our ophthalmic therapy pipeline by developing ocular anti-allergic drugs, where we expect Dr. Biro's 18 years of experience in this specialty field to be invaluable."
By Steve Elliott
Electronic cigarettes containing extracts of marijuana -- but no psychoactive THC -- are about to hit the market in France any day now. The e-cigs contain cannabinoids, including cannabidiol (CBD), which give relaxing and pain-killing effects, according to the manufacturer.
Three young French entrepreneurs are launching the product, which launches before the end of December, and they claim it will be entirely legal, reports The Local.
"KanaVape brings you many of the benefits of cannabinoids without the psychotic effect of THC," claims the website of the product, due to go on sale this month in France.
"Vape pens" which allow consumers to inhale cannabis or tobacco vapor are increasingly popular in the United States. But they've been rare in Europe until now.
"By using only hemp with 5 percent CBD (Cannabidiol) and no THC, KanaVape provides you with a unique cannabinoids excperience," the company claims. "Cannabidiol is a non-psychotic cannabinoid, it will not make you 'high' but will help you relax." (Note the not-very-subtle substitution of the word "psychotic" for the proper term, "psychoactive," perhaps to demonize THC and make it seem more threatening -- a favorite, albeit quite deceptive, marketing strategy for "CBD-only" purveyors.)
CBD-rich hemp, which is grown legally to make products such as oil, rope, cloth, paper, and fuel, will be used to make the vapor mix.
PuraMed BioScience, Inc., a company which researches, develops, and markets over-the-counter (OTC) medicinal and healthcare products on Friday announced it is nearing the completion of development of its new non-prescription, hemp-based, homeopathic medication for treatment of epilepsy symptoms including seizures and seizure-related headaches.
Both epilepsy and migraines appear to be triggered by the same cortical spreading depression (CSD) in the brain; the difference is the rate of reaction. This may be why many people who suffer from migraines are prescribed epilepsy medications.
The third most common neurological disorder in the US, epilepsy affects about 2.7 million people, with children and older adults being most susceptible. The condition also causes up to 50,000 sudden deaths each year.
Recent research has shown cannabidiol (CBD), a non-psychoactive cannabinoid found in both hemp and marijuana varieties of cannabis, to be an effective therapy in the treatment of epilepsy symptoms.
"By incorporating standardized hemp oil into our current patented, over-the-counter migraine relief formula, MigraPure, we believe we can offer relief to people who not only suffer with migraines, but also offer relief to people who have seizure-related headaches and other epilepsy-type symptoms," said Russ Mitchell, CEO at PuraMed BioScience.
Two thirds of Canadians currently using medical cannabis do so to ease arthritis pain
By Steve Elliott
In a position paper issued on Tuesday, The Arthritis Society called for more research into the efficacy and safety of medical cannabis as a therapy to alleviate symptoms of pain and fatigue caused by the chronic disease.
“More and more Canadians are accessing medical cannabis as a treatment option for severe arthritis symptoms,” explained Society president and CEO Janet Yale. “We have a duty to the people we serve to ensure that the scientific basis for the use of medical cannabis is clear and appropriate, with patient safety and improved care our foremost priorities.”
Thousands of Canadians have already received authorization from Health Canada to use medical cannabis and as many as two-thirds of those people are using the drug to help manage pain due to arthritis.
"There is much still unknown about the treatment therapy, its safety and its efficacy for coping with arthritis – leading to potential risks for patients," the Arthritis Society release claims, although if they simply asked the arthritis patients involved, they'd be talking less about risks and more about benefits.
The anecdotal evidence in support of medical cannabis for arthritis pain is very robust, and Tuesday's announcement will ensure that more clinical research will be conducted to further validate this treatment modality, according to CanniMed Ltd., the first producer to be licensed under the new Canadian Marihuana for Medical Purposes Regulations (MMPR).
By Steve Elliott
Some political candidates seem to be in denial about their marijuana use, but a write-in candidate for governor of Rhode Island wants to make sure voters know she uses cannabis every day for both cooking and medicinal purposes.
"Yes, I do smoke cannabis, and yes, I do inhale," says Anne Armstrong in a campaign video posted online this month, reports Sam Levine at The Huffington Post. "It helps me. It helps me to focus, it helps to facilitate communication."
Armstrong posted on her Facebook page that she wants a state where "common sense, compassion, and cooperation can recreate Rhode Island into a place where everyone can live in abundance."
"It doesn't make people crazy, the way you've been told," Armstrong says of marijuana in the ad. "I hope that you will read and open your eyes and realize the truth that we've been lied to for a long time by our government."
Armstrong said in a speech earlier this month at Boston Hempfest that if she were elected governor, she would eliminate all penalties for growing, sharing and using cannabis in Rhode Island.
"I'm gonna site and use cannabis as I govern from my office," Armstrong said. "And I am gonna have my cannabis in the rotunda of the Statehouse and it is gonna be a people's cannabis garden."
Rhode Island permits the cultivation and use of marijuana for certain medical conditions.
By Steve Elliott
Researchers have tried for years to enhance the fear extinction learning that lies at the heart of exposure-based therapies for post-traumatic stress disorder. Those approaches are considered the best we have for anxiety disorders, yet they often fall short. A group at the University of Michigan is trying to get at the mechanics of learning to see if cannabinoids like THC can help with PTSD, since cannabinoid receptors are present in areas of the brain crucial for emotional learning and memory.
"Our work is driven by the discovery that endocannabinoids are existing modulators in regular memory processes," Israel Liberzon, M.D., told Aaron Levin at Psychiatric News.
Work on the role of cannabinoids is relatively new, noted research fellow Christine Rabinak, Ph.D. The first paper showing how cannabinoid receptors affect fear learning in rats appeared in the scientific journal Nature only in 2002.
The work of Rabinak, Liberzon, and others has now expanded cannabinoid research from rodents into human subjects.
They and several colleagues report in a paper published in Neuropharmacology in January the results of a study in which they gave 14 healthy volunteers THC orally prior to extinction learning and compared them to 15 others who received a placebo.
By Steve Elliott
The pulmonary impact of smoking marijuana regularly is far less than that of smoking tobacco, according to a comprehensive new review of the published evidence conducted by Dr. Donald P. Tashkin, emeritus professor of medicine and medical director of the pulmonary function laboratory at the University of California, Los Angeles.
Habitual marijuana use alone doesn't appear to lead to significant abnormalities in lung function, according to the report, nor does it increase the risks of chronic obstructive pulmonary disease (COPD) or either lung cancer or upper airway cancer, reports Bruce Jancin at The Oncology Report.
Smoking marijuana is, however, associated with an increase in symptoms of chronic bronchitis (due to inhaling the smoke); but these symptoms go away upon discontinuation of use, according to Dr. Tashkin (Ann. Am. Thorac. Soc. 2013;10:239-47).
"The accumulated weight of evidence implies far lower risks for pulmonary complications of even regular heavy use of marijuana, compared with the grave pulmonary consequences of tobacco," Dr. Tashkin concluded.
Dr. Tashkin's article is "the most comprehensive and authoritative review of the subject ever published," according to an accompanying editorial by Dr. Mark A. Ware.
By Steve Elliott
A new study from Stanford University suggests that marijuana can be helpful and therapeutic not only to older people with conditions like cancer, glaucoma, and AIDS, but also to younger people with autism.
The study shows that mutations associated with autism block the action of endocannabinoids, naturally occurring brain molecules that act on the same receptors that marijuana's active chemical, THC, acts on, reports Autism Daily Newscast (ADN).
According to the findings, cannabis could be used as a treatment to autism, since the phytocannabinoids found in it can unblock that disruption in the body's cannabinoid receptors.
That cannabis affects autism in a possibly therapeutic way adds to the chorus of parents with Attention Deficit Hyperactivity Disorder (ADHD) who have suggested that the mild sedative properties of marijuana can supplement or even negate the need for stimulant, speed-like drugs such as Ritalin and Adderall currently used to treat the condition, reports The Inquisitr.
By Steve Elliott
Sativex, the 50:50 combination of THC (tetrahydrocannabinol) and CBD (cannabidiol) in oral spray form, made by GW Pharmaceuticals, is now available in Italy, GW's partner company Almirall announced on Monday.
Sativex is available in Italy as a prescription medicine for treatment of moderate to severe spasticity in multiple sclerosis (MS) patients who have not responded to other anti-spasticity medicines. The launch follows full marketing authorization for Sativex by Italian health authorities in May.
The medication is reimbursed by Italian authorities as a Class H (hospital dispensed) medicine. The reimbursed price of Sativex granted by government authorities in Italy is consistent with the reimbursed price of Sativex in Spain, according to GW.
"As one of the largest markets in Europe, the launch of Sativex in Italy is a key milestone in the commercialization of this important new medicine," said Justin Gover, chief executive officer of GW. "Italy represents yet another addition to the growing number of countries in Europe in which Sativex is now available to treat MS spasticity, a particularly debilitating symptom of MS that is not adequately treated with currently available medications.
By Steve Elliott
In a first-of-its-kind study on the biochemical impact of psychological trauma, researchers have discovered a connection between the amount of cannabinoid receptors in the human brain and the chronic, disabling condition post-traumatic stress disorder (PTSD).
The findings, from New York University Langone Medical Center, appeared online Tuesday in the journal Molecular Psychiatry, reports Science Daily. They will also be presented this week at the annual meeting of the Society of Biological Psychiatry in San Francisco.
There are a number of treatments using psychotherapy and cognitive behavioral therapy for PTSD patients, but these methods aren't always available, reports Loren Grush at Fox News.
No pharmaceutical treatments have yet been developed to specifically target PTSD.
The NYU Langone Center researchers utilized brain imaging technology to highlight the connection between the number of cannabinoid receptors in the brain and PTSD. The cannabinoid receptors, known as CB1 receptors, are activated in the brain when a person uses marijuana, which can lead to impaired short-term memory and reduced anxiety.
By Czech News Agency
Prague - Czech-born chemistry professor Lumir Ondrej Hanus was Thursday presented with the Czech Addiction Science Award for his discovery of cannabinoids proper to the human body with which he has opened the door to further research into and use of hemp for treatment.
Hanus, who left for Jerusalem after 1989 and is active at the Hebrew University, "is a world-recognised capacity and a pioneer of the use of a substance that was primarily considered a substance abused as a drug," Jindrich Voboril, Czech national anti-drug coordinator, told CTK.
Hanus considers hemp one of the safest medicines. He is against its legalisation for recreational purposes and he disagrees with that hemp can be used for prevention of diseases.
During his recent stay in the Czech Republic Hanus explained his discovery saying there are bonding points in the brain to which cannabinoids produced by the body are bound. If the system is disrupted, the person concerned falls ill. The balance of the system is restored if hemp-based substances are administered and the health condition improves.
On this principle hemp alleviates strong pains and improves the condition of cancer and multiple sclerosis patients.
Thanks to Hanus' discoveries, Israel has changed the relevant law allowing hemp to be used as a medicine and it is covered by health insurance.